Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion

✍ Scribed by B. Bode-Lesniewska; S. Frigerio; U. Exner; M. T. Abdou; H. Moch; D. R. Zimmermann

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 849 KB
• Volume: 46
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/gcc.20478

✦ Synopsis

Abstract

The clinical course of myxoid/round cell liposarcoma (MRCL) is characterized by frequent local recurrences and metastases at unusual sites. MRCLs carry specific translocations, t(12;16) or rarely t(12;22), linking the FUS or the EWSR1 gene with the DDIT3 gene, respectively. Nine FUS/DDIT3 and three EWSR1/DDIT3 variants of fusion transcripts have been described thus far. In search of prognostic markers for MRCL, we analyzed the translocation types of 31 patients and related them to the event free and overall survival. Using break‐apart FISH and RT‐PCR combined with DNA sequencing, we detected FUS/DDIT3 fusions in 30 sarcomas, while an EWSR1/DDIT3 translocation was identified in one tumor. FUS/DDIT3 type II (exons 5‐2) was most commonly detected (20 cases), followed by type I (7‐2) (7 cases) and type III (8‐2) (3 cases). A single tumor carrying a t(12;22) translocation expressed a hitherto unknown EWSR1‐DDIT3 fusion transcript (13‐3) linking the complete RNA‐binding domain of EWSR1 with a short piece of the 5′‐UTR and the entire open reading frame of the DDIT3 gene. Interestingly, five of six patients with type I (7‐2) FUS/DDIT3 fusions displayed local recurrences and/or metastatic spread within the first 3 years, generally requiring chemotherapeutical treatment (median disease‐free survival 17 months). In contrast, 9 of 13 patients with type II FUS/DDIT3 translocations remained at 3 years disease‐free (median disease‐free survival 75 months). Since the total number of patients is still limited, further studies are required to verify a putative association of type I FUS/DDIT3‐fusion transcripts with a prognosis of MRCL. © 2007 Wiley‐Liss, Inc.